Clinical Trial

A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors

Study acronym: GW01-200-01
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-15
Trial Details
NCT Number NCT07629258
Lead Sponsor Groovy Medicine (Hangzhou) Ltd.
Conditions Advanced Tumors
Enrollment 100 participants
Start Date 2026-07-17
Primary Completion 2029-01 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14